0SZI Stock Chart & Stats
$9.22
-$0.08(-0.92%)
At close: 4:00 PM EDT
$9.22
-$0.08(-0.92%)
Day’s Range― - ―
52-Week Range$7.13 - $24.50
Previous CloseN/A
Volume5.39K
Average Volume (3M)4.42K
Market Cap
$218.75M
Enterprise Value$68.37
Total Cash (Recent Filing)$117.94M
Total Debt (Recent Filing)$4.26M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Nov 10, 2026EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.19
Shares Outstanding19,341,293
10 Day Avg. Volume2,270
30 Day Avg. Volume4,422
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$39.17Price Target Upside324.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-5.36
Revenue Forecast (FY)$1.67M
Bulls Say, Bears Say
Bulls Say
Liquidity RunwayThe expected funding runway into 2028 gives Corbus time to execute late-stage trials and reach important clinical milestones without immediate financing pressure, supporting continuity in a capital-intensive development cycle.
Regulatory ProgressFDA clearance for a registrational Phase 3 study materially advances CRB-701 toward potential approval and commercialization. It also provides a clearer development path for the company’s lead oncology asset over the next several quarters.
Clinical DifferentiationThe reported response rates and durable responses support CRB-701’s potential in underserved HPV-driven cancers. If confirmed in registrational studies, this profile could improve Corbus’s competitive position in targeted ADC oncology.
Bears Say
No Product RevenueCorbus has no recurring product revenue because it remains a clinical-stage company. This leaves financial performance dependent on external funding or business-development transactions until a candidate is successfully commercialized.
Widening Net LossesThe sharp increase in net losses reflects a materially higher operating cost base as programs advance. Sustained losses reduce equity over time and increase the capital required to reach regulatory and commercial milestones.
Accelerating Cash BurnOperating cash burn has accelerated substantially while the company remains pre-revenue. Even with liquidity projected into 2028, continued spending raises the likelihood of future equity, debt, or partnership financing.
Corbus Pharmaceuticals News
0SZI FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest share price was $7.13 and its highest was $24.50 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $218.75M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 74 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$1.81 earnings per share for the quarter, missing the consensus estimate of -$1.259 by -$0.551.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.21.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 19,341,293 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.81 in its last earnings report, missing expectations of -$1.259. Following the earnings report the stock price went up 0.521%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0SZI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corbus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.17 (324.80% Upside)
$39.17 (324.80% Upside)
Blogger Sentiment
Bullish
GB:0SZI Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $126.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.52%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
0SZI Stock 12 Month Forecast
Average Price Target
$39.17
▲(324.80% Upside)